Lexeo Therapeutics Inc（LXEO）财务数据LXEOLexeo Therapeutics Inc

Evaluating the bottom line, Lexeo Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -46.76%, provide a clear picture of how effectively LXEO converts its operational activities into shareholder value.

In the context of the broader market, LXEO competes directly with industry leaders such as GALT and LRMR. With a market capitalization of $397.10M, it holds a significant position in the sector. When comparing efficiency, LXEO's gross margin of N/A stands against GALT's N/A and LRMR's N/A. Such benchmarking helps identify whether Lexeo Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Lexeo has reported consistent net losses, with Q2 2026 showing a net loss of $25,867,000. The company's EPS for Q2 2026 was -0.30, reflecting ongoing challenges in profitability. However, the current ratio is strong at 13.89, indicating good liquidity.